The association between hemoglobin concentration and clinical outcomes after aneurysmal subarachnoid hemorrhage : Insights from the LongTEAM registry
© 2023 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd..
OBJECTIVE: The aim of this study is to explore whether preoperative hemoglobin levels could serve as a prospective biomarker for early brain injury in patients with aneurysmal subarachnoid hemorrhage (aSAH). This investigation seeks to discern its association with postoperative complications and unfavorable clinical outcomes.
METHODS: We conducted a comprehensive analysis of data derived from the LongTeam registry, including patients with aSAH diagnosed between January 2015 and September 2021. These patients were stratified into three distinct groups based on their hemoglobin levels: anemic, standard, and elevated HGB. We employed logistic models featuring spline transformations to assess the relationship between HGB levels and in-hospital complications. Furthermore, a multivariate Cox proportional hazard model was employed to estimate the impact of elevated hemoglobin levels on the hazard function, which was elucidated through Kaplan-Meier curves.
RESULTS: Our study comprised a total of 988 patients, among whom 115 (11.6%) presented preoperative anemia, and 63 (6.4%) exhibited elevated preoperative HGB levels. Following adjustments for potential confounding factors, no significant disparity in risk was evident between anemic patients and those with standard HGB levels. However, individuals with elevated HGB levels displayed a heightened incidence and an increased risk of developing deep vein thrombosis (DVT, odds ratio [OR] = 2.39, 95% confidence interval [CI] = 1.16-4.91, p = 0.018; hazard ratio [HR] = 2.05, 95% CI 1.08-3.92, p = 0.015). Aberrant HGB concentrations did not demonstrate an association with other clinical outcomes.
CONCLUSION: Our findings emphasize that abnormal HGB levels show no association with adverse outcomes at the 90 days mark after accounting for clinical confounding factors in patients with aSAH. Simultaneously, the study illuminates the potential of HGB as an early indicator for identifying patients at a heightened risk of developing DVT.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
CNS neuroscience & therapeutics - 30(2024), 4 vom: 18. Apr., Seite e14506 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lin, Fa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aneurysmal subarachnoid hemorrhage |
|---|
| Anmerkungen: |
Date Completed 16.04.2024 Date Revised 25.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/cns.14506 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363419608 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363419608 | ||
| 003 | DE-627 | ||
| 005 | 20240425232420.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cns.14506 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM363419608 | ||
| 035 | |a (NLM)37849416 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lin, Fa |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The association between hemoglobin concentration and clinical outcomes after aneurysmal subarachnoid hemorrhage |b Insights from the LongTEAM registry |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd. | ||
| 520 | |a OBJECTIVE: The aim of this study is to explore whether preoperative hemoglobin levels could serve as a prospective biomarker for early brain injury in patients with aneurysmal subarachnoid hemorrhage (aSAH). This investigation seeks to discern its association with postoperative complications and unfavorable clinical outcomes | ||
| 520 | |a METHODS: We conducted a comprehensive analysis of data derived from the LongTeam registry, including patients with aSAH diagnosed between January 2015 and September 2021. These patients were stratified into three distinct groups based on their hemoglobin levels: anemic, standard, and elevated HGB. We employed logistic models featuring spline transformations to assess the relationship between HGB levels and in-hospital complications. Furthermore, a multivariate Cox proportional hazard model was employed to estimate the impact of elevated hemoglobin levels on the hazard function, which was elucidated through Kaplan-Meier curves | ||
| 520 | |a RESULTS: Our study comprised a total of 988 patients, among whom 115 (11.6%) presented preoperative anemia, and 63 (6.4%) exhibited elevated preoperative HGB levels. Following adjustments for potential confounding factors, no significant disparity in risk was evident between anemic patients and those with standard HGB levels. However, individuals with elevated HGB levels displayed a heightened incidence and an increased risk of developing deep vein thrombosis (DVT, odds ratio [OR] = 2.39, 95% confidence interval [CI] = 1.16-4.91, p = 0.018; hazard ratio [HR] = 2.05, 95% CI 1.08-3.92, p = 0.015). Aberrant HGB concentrations did not demonstrate an association with other clinical outcomes | ||
| 520 | |a CONCLUSION: Our findings emphasize that abnormal HGB levels show no association with adverse outcomes at the 90 days mark after accounting for clinical confounding factors in patients with aSAH. Simultaneously, the study illuminates the potential of HGB as an early indicator for identifying patients at a heightened risk of developing DVT | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a aneurysmal subarachnoid hemorrhage | |
| 650 | 4 | |a deep vein thrombosis | |
| 650 | 4 | |a hemoglobin | |
| 650 | 4 | |a outcome | |
| 650 | 4 | |a treatment | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Hemoglobins |2 NLM | |
| 700 | 1 | |a Lu, Changyu |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Runting |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Heze |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Yuanli |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xiaolin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Jizong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t CNS neuroscience & therapeutics |d 2008 |g 30(2024), 4 vom: 18. Apr., Seite e14506 |w (DE-627)NLM17958930X |x 1755-5949 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2024 |g number:4 |g day:18 |g month:04 |g pages:e14506 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/cns.14506 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2024 |e 4 |b 18 |c 04 |h e14506 | ||